Evelien Moorkens1, Arnold G Vulto2,3, James Kent4, Lindsay McClure5, Richard Boldero6, Thibault Vanhove7, Steven Simoens1, Isabelle Huys1. 1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 2. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. a.vulto@gmail.com. 3. Hospital Pharmacy, The Erasmus University Medical Center, Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. a.vulto@gmail.com. 4. Specialist Pharmacy Service, NHS England, London, UK. 5. NHS National Services Scotland, Edinburgh, UK. 6. All Wales Therapeutics and Toxicology Centre, NHS Wales, Cardiff, UK. 7. AZ Sint-Maarten, Mechelen, Belgium.
Abstract
BACKGROUND: Regions within England, Scotland and Wales show variation in rate of adoption of biosimilar infliximab and etanercept. OBJECTIVES: This study aims to examine how local decisions and practices in regions within England, Scotland and Wales might explain initial variation in market dynamics of biosimilar and originator infliximab and etanercept. METHODS: Market data provided by the National Health Service (NHS) on biosimilar and originator infliximab and etanercept uptake were analysed for the 10 historical regions of England, 14 health boards in Scotland and 7 health boards in Wales (2015-2018). Findings were discussed in ten semi-structured interviews: on a national level with an industry representative (1), on a regional level with NHS employees in England (6), Scotland (1) and Wales (1), and on a local level with a representative of a clinical commissioning group in England (1). RESULTS: Tenders for infliximab and etanercept in England, Scotland and Wales have consistently resulted in a biosimilar as the best value biological. Early and late biosimilar adopters are seen, with overall convergence towards high biosimilar market shares over time. Qualitative results suggest that biosimilar adoption was positively influenced by (a) a price difference between biosimilar and originator product making it worthwhile to switch patients; (b) a good relationship between commissioner and provider in England resulting in gain share agreements; (c) leadership on biosimilars in regional NHS offices in England or Scottish and Welsh health boards; (d) key opinion leaders or leading hospitals that start using biosimilars early and gain experience. CONCLUSIONS: This study has shown that the savings potential drives biosimilar use. Regions with a proactive attitude, good stakeholder relationships, and clinician engagement were identified as early adopters.
BACKGROUND: Regions within England, Scotland and Wales show variation in rate of adoption of biosimilar infliximab and etanercept. OBJECTIVES: This study aims to examine how local decisions and practices in regions within England, Scotland and Wales might explain initial variation in market dynamics of biosimilar and originator infliximab and etanercept. METHODS: Market data provided by the National Health Service (NHS) on biosimilar and originator infliximab and etanercept uptake were analysed for the 10 historical regions of England, 14 health boards in Scotland and 7 health boards in Wales (2015-2018). Findings were discussed in ten semi-structured interviews: on a national level with an industry representative (1), on a regional level with NHS employees in England (6), Scotland (1) and Wales (1), and on a local level with a representative of a clinical commissioning group in England (1). RESULTS: Tenders for infliximab and etanercept in England, Scotland and Wales have consistently resulted in a biosimilar as the best value biological. Early and late biosimilar adopters are seen, with overall convergence towards high biosimilar market shares over time. Qualitative results suggest that biosimilar adoption was positively influenced by (a) a price difference between biosimilar and originator product making it worthwhile to switch patients; (b) a good relationship between commissioner and provider in England resulting in gain share agreements; (c) leadership on biosimilars in regional NHS offices in England or Scottish and Welsh health boards; (d) key opinion leaders or leading hospitals that start using biosimilars early and gain experience. CONCLUSIONS: This study has shown that the savings potential drives biosimilar use. Regions with a proactive attitude, good stakeholder relationships, and clinician engagement were identified as early adopters.
Authors: Violeta Razanskaite; Marion Bettey; Louise Downey; Julia Wright; James Callaghan; Miles Rush; Simon Whiteoak; Sarah Ker; Kim Perry; Caron Underhill; Eren Efrem; Iftikar Ahmed; Fraser Cummings Journal: J Crohns Colitis Date: 2017-06-01 Impact factor: 9.071
Authors: Evelien Moorkens; Arnold G Vulto; Isabelle Huys; Pieter Dylst; Brian Godman; Simon Keuerleber; Barbara Claus; Maria Dimitrova; Guenka Petrova; Ljiljana Sović-Brkičić; Juraj Slabý; Robin Šebesta; Ott Laius; Allan Karr; Morgane Beck; Jaana E Martikainen; Gisbert W Selke; Susan Spillane; Laura McCullagh; Gianluca Trifirò; Patricia Vella Bonanno; Asbjørn Mack; Antra Fogele; Anita Viksna; Magdalena Władysiuk; Helder Mota-Filipe; Dmitry Meshkov; Marija Kalaba; Simona Mencej Bedrač; Jurij Fürst; Corrine Zara; Peter Skiöld; Einar Magnússon; Steven Simoens Journal: PLoS One Date: 2017-12-28 Impact factor: 3.240
Authors: Evelien Moorkens; Steven Simoens; Per Troein; Paul Declerck; Arnold G Vulto; Isabelle Huys Journal: BioDrugs Date: 2019-06 Impact factor: 5.807
Authors: Evelien Moorkens; Steven Simoens; Per Troein; Paul Declerck; Arnold G Vulto; Isabelle Huys Journal: BioDrugs Date: 2019-06 Impact factor: 5.807